The Effectiveness of Conjugate Haemophilus influenzae Type B Vaccine in The Gambia 14 Years After Introduction | Zendy

S. Howie | Zendy; Claire Oluwalana | Zendy; Ousman Secka | Zendy; Susana Scott | Zendy; Readon C Ideh | Zendy; Bernard E. Ebruke | Zendy; Anne Balloch | Zendy; Sana Sambou | Zendy; Jamie Erskine | Zendy; Y. Lowe | Zendy; Tumani Corrah | Zendy; R. A. Adegbola | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Effectiveness of Conjugate Haemophilus influenzae Type B Vaccine in The Gambia 14 Years After Introduction

Author(s) -

S. Howie,

Claire Oluwalana,

Ousman Secka,

Susana Scott,

Readon C Ideh,

Bernard E. Ebruke,

Anne Balloch,

Sana Sambou,

Jamie Erskine,

Y. Lowe,

Tumani Corrah,

R. A. Adegbola

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit598

Subject(s) - medicine , hib vaccine , conjugate vaccine , pediatrics , booster dose , carriage , vaccination , incidence (geometry) , haemophilus influenzae , meningitis , immunization , immunology , antibody , antibiotics , physics , microbiology and biotechnology , optics , pathology , biology

The Gambia was the first country in Africa to introduce conjugate Haemophilus influenzae type b (Hib) vaccine, which, as in other developing countries but unlike industrialized countries, is delivered as a 3-dose primary series with no booster. This study assessed its effectiveness 14 years after introduction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research